Abstract: The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

Abstract: Provided herein, inter alia, are a carbon fiber-reinforced polymer composite and a method for manufacturing the same. The carbon fiber-reinforced polymer composite may improve interfacial bonding force by modifying the surface of carbon fibers with an amphiphilic block copolymer and then forming a composite of the surface-modified carbon fibers with a polymer.

Abstract: Water filtration membranes are provided. Such membranes include polysaccharide fibers that have been modified to possess thiol groups thereon, resulting in materials that effectively bind heavy metal ions. The resulting fibers may be used by themselves or applied to a scaffold to form a membrane suitable for removing heavy metals from water, including groundwater.

Abstract: The invention generally relates to mass spectrometry probes and systems for ionizing a sample. In certain embodiments, the invention provides a mass spectrometry probe including a substrate in which a portion of the substrate is coated with a material, a portion of which protrudes from the substrate.

Abstract: Random copolymers, crosslinked thin films of the random copolymers and cell culture substrates comprising the crosslinked thin films are provided. Also provided are methods of making and using the copolymers, thin films and substrates. The copolymers are polymerized from glycidyl methacrylate monomers and vinyl azlactone monomers. The crosslinked thin films are substrate independent, in that they need not be covalently bound to a substrate to form a stable film on the substrate surface.

Abstract: A speech intelligibility system. Embodiments comprise a talker unit, a listener unit and an earpiece. The talker unit includes a microphone to receive audible speech content and to produce electrical signals representative of the speech content, and a transmitter coupled to the microphone to produce wireless transmissions containing the speech content. The listener unit includes a receiver to receive the wireless transmissions and to produce electrical signals representative of the speech content. At least one of the talker unit and the listener unit includes an amplifier to amplify spectral components of the speech content within a frequency range having a lower end between about 800 Hz and 1,700 Hz and an upper end between about 7,000 Hz and 11,000 Hz. The earpiece is coupled to the listener unit and includes a speaker to produce audible speech content having the amplified spectral components and a tube to direct the audible speech content from the speaker toward a user's ear canal.

Abstract: A method for transmitting downlink data in a multicast scheme by a base station in a wireless communication system is disclosed. The method includes receiving a first request signal requesting first data from a first user equipment (UE), receiving a second request signal requesting second data from a second UE, generating a transmission message by applying an exclusive OR (XOR) operation to the first data and the second data, and transmitting the transmission message to the first UE and the second UE in the multicast scheme.

Abstract: A therapeutic composition can include an amount of amniotic fluid having a therapeutically effective amount of at least one protein, hyaluronic acid, or both. The therapeutic composition can be substantially free of lanugo, vernix, and cells harvested with the amniotic fluid.

Abstract: This document provides methods and materials for reducing scar formation (e.g., scar formation during wound healing) and/or for reducing keloid formation (e.g., keloid formation that occurs during wound healing or keloid formation that does not occur during wound healing). For example, methods and materials for topically administering pentamidine to reduce scar formation and/or to reduce keloid formation are provided.

Abstract: The present disclosure provides FGF1 mutant proteins having one or more mutations in the heparin binding domain. Such mutants may also have an N-terminal deletion, point mutation(s), or combinations thereof. In some examples, the mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.

Abstract: Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.

Abstract: A channel distribution system has a channel carrying content, and an interactive receiver which receives content and provides to a user. The interactive receiver has an interface to allow the user to interact with the content. The channel also includes a broadcast label superimposed on the content which invites the user to interact with the content. The label includes an interactive link with a digital instruction containing handling information for the interactive receiver device. The handling information tells the interactive receiver how to handle a user interaction coinciding with the label.

Abstract: This document provides materials and methods involved in making and using induced pluripotent stem cells (iPSCs). For example, measles virus vectors for reprogramming somatic cells into iPSCs, methods for obtaining iPSCs, and methods for using iPSCs are provided.

Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.

Abstract: The present disclosure is directed to an anatomical model and methods for using the same. The anatomical model of the present disclosure includes a plurality of simulated bodily structures that emulate the naturally occurring structures (e.g., organs, bones, and tissue) of the human body. The anatomical model of the present disclosure can be used to simulate clinical conditions observed in infant subjects and carry out medical procedures and interventions commonly practiced by clinicians under real-life conditions.

Abstract: A system and method for generating hydrogen gas from an aqueous solution are disclosed herein. The system comprises a compartment with a working electrode for reducing water in response to an applied voltage to generate hydrogen and a redox-active electrode capable of reversibly undergoing oxidation and reduction. The system may further comprise a second compartment with a working electrode for generating oxygen and redox-active electrode electrically connectable to the redox-active electrode in the first compartment. The method comprises applying a voltage between a working electrode and a redox-active electrode of a system described herein and/or between comprising a working electrode of one compartment and a working electrode of a second compartment of a system described herein.

Abstract: The present disclosure relates to novel sesquiterpenoid compounds as SHP2 and/or POLE3 inhibitors for potential treatment for cancers, and to methods of making and using the sesquiterpenoid compounds. The present invention therefore provides a method of using the disclosed compounds as chemosensitizations agent to a DNA damaging drugs for cancers.

Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including cyclic and heterocyclic anilide rings and their synthetic precursors, and mono-, di-, or multi-substituted N-heterocyclic rings, R-isomers, non-hydroxylated and/or non-chiral propanamides in treating androgen receptor dependent diseases and conditions such as hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutam

Abstract: A system for and methods of analyzing a test sample through the use of a rotary apparatus that includes a microfluidic paper-based apparatus (mPAD). The apparatus includes two or more layers that are rotatable with respect to one another. A middle layer may comprise a microfluidic apparatus having one or more reagent channels. Each of the reagent channels may include reagent dried on the surface of the channel, and, together with an adsorption pad, may be aligned vertically with a sample chamber. Male and female engagement surfaces on each of the middle layer, the top layer, and the bottom layer interlock to secure each layers in vertical alignment so that fluid flows through the apparatus to contact a test sample with a reagent and facilitate detection of a target analyte in the test sample in the sample chamber.

Abstract: The present invention provides a method of inhibiting release of a virus from a cell, comprising contacting the cell with a compound that binds an ubiquitin E2 variant (UEV) domain of a cellular polypeptide, or fragment thereof, with an affinity sufficient to inhibit or disrupt the binding of the cellular polypeptide, or fragment thereof, to ubiquitin.